Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03582774 · ClinicalTrials.gov registry record · Phase 3
Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy
A Phase 3 study of Recurrent Prostate Carcinoma, sponsored by Jonsson Comprehensive Cancer Center.
- Active
- Registry status
- Phase 3
- Development phase
- 193
- Enrollment target
- 2
- Study locations
NCT03582774 is a Phase 3 study of Recurrent Prostate Carcinoma that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 193 participants, above the 159-participant average among 29 other Recurrent Prostate Carcinoma trials with a reported enrollment target (21% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT03582774, a Phase 3 study of Recurrent Prostate Carcinoma, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 193 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase III trial studies how well Gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) positron emission tomography (PET)/computed tomography (CT) works in diagnosing participants with prostate cancer that has come back after surgery. 68Ga-PSMA-11 are taken up by cancer cells. Diagnostic procedures, such as PET/CT scans, may help find and diagnose prostate cancer and find out how far the disease has spread. Giving 68Ga-PSMA-11 with PET/CT may help doctors plan better for salvage radiation therapy in participants with recurrent prostate cancer.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Positron Emission Tomography
- OTHER Best Practice
- RADIATION Gallium Ga 68-labeled PSMA-11
Study Locations (2)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
- UCSF Medical Center-Mount Zion - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2018-07-12 |
| Est. Completion | 2027-07-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03582774
The ClinicalTrials.gov registry entry for NCT03582774 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 159-participant average among 29 other Recurrent Prostate Carcinoma trials with a reported enrollment target (21% higher). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Prostate Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Computed Tomography is the first listed.
NCT03582774 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03582774 about?
NCT03582774 is a clinical study titled "Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy". This phase III trial studies how well Gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) positron emission tomography (PET)/computed tomography (CT) works in diagnosing participants with prostate cancer that has come back after surgery. 68Ga-PSMA-11 are taken up by cancer cells. Diagnostic procedures, suc...
What is the current status of trial NCT03582774?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 193 participants. The study started on 2018-07-12. Estimated completion is 2027-07-12.
What conditions does trial NCT03582774 study?
This clinical trial studies the following conditions: Recurrent Prostate Carcinoma.
What interventions are being tested in trial NCT03582774?
The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Best Practice (OTHER), Gallium Ga 68-labeled PSMA-11 (RADIATION).
Who is sponsoring clinical trial NCT03582774?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03582774 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
RECRUITING · Phase 3
-
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
COMPLETED · Phase 3
-
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
RECRUITING · Early Phase 1
-
Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers
RECRUITING · Phase 2
-
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
RECRUITING
-
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.